Research article · Nov 2022
Conference abstractPublished 29 Sep 2014
AHCC use and one daring hypothesis
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Case Report: An 84 years old woman was living in a city near Caxias do Sul. At the initial visit at her home (November 2012), she weighed 36 Kg, and a height 1m 60 cm. She complained of weakness, malaise, loss of appetite, fatigue, bad digestion, and depression. Her daughter, informed that two years ago, her mother had one episode of fainting, and in the last eight months had been progressively losing weight, more depressed, with insomnia, dry eyes, dry mouth, no appetite, swallowing difficulty, bad digestion, weakness, under-nutrition, and slow movements. At physical examination signals of malnutrition were obvious (frail, space between ribs, subcutaneous tissue almost absent, bones prominent. Her BMI was 14.06). The presence of malnutrition was evident, triggered by hypothyroidism, and Sjögren disease, confirmed by complementary tests. Biochemical tests and salivary scintigraphy were conducted to the diagnosis. Our clinical treatment started on Nov 22, 2012, taking in account all her daily needs she was treated by adding levothyroxine 50 mcg daily, and AHCC [Active Hexose Correlated Compound (a bioactive nutrient)] 1g 3 times a day. Evolution: Her course was of evident of recovery; in less than one month she presented eye tears, tongue humidity, and gradually improved food taste, appetite, and a better mood. Last March 2013, she has sustained improvements. She gained weight, no more fatigue, also improved her mood, and in her last evaluation, on April 06 2013, she was weighing 50 Kg, and her BMI was 19.5. At present the patient is using AHCC 1 g 3 times a day, and is clinically well, without the complaints referred before her treatment. The cascade of clinical normalization appeared after AHCC use. In synthesis, we want to emphasize the cascade of favorable clinical events sparked by AHCC use, continue to sustain today. She was met last June 23, 2014, weighing 55 kg, BMI is 21.5, all her previous complaints alleviated after the AHCC treatment. Subsequently 5 more patients have been added to the study and thus far they all are showing similar path to improvement. AHCC: Non Absorbable Glucides (NAG) like AHCC, Inulin, FOS act as Prebiotics, but AHCC exerts distinguished pleiotropic singular kind of actions as seen from many published literature. It is isolated from hybridization of several species of mushroom mycelia, in a patented process of cultivation. Its formula presents Polysaccharides (alpha-glucans, beta-glucan and activated hemicellulose), glycoproteins and amino acids. Particularly rich in alpha-glucans (important nutrients), which has an active component of acetylated alpha- glucans that possess attributed capacity to enhance the immune system. These are low molecular weight (under 5000 Daltons) structures and increase the efficiency of its nutrient assimilation and utilization by the GI tract as well cells of the immune system strengthening the defense; more is absorbed and used than eliminated.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Editorial · 3 Jan 2015
Worlds Based on Subtle Differences An Inclusive one for all Hypothesis
Conference abstract · 2021
Evaluation of Active Hexose Correlated Compound (Ahcc) on Phase Ii Drug Metabolism Pathways and the Implications for Supplement-Drug Interactions
Research article · 2015
Evaluation of Active Hexose Correlated Compound (Ahcc) on Phase Ii Drug Metabolism Pathways and the Implications for Supplement-Drug Interactions
Research article · 2015
Attenuation of Pulmonary Mycobacterium Avium Disease by Active Hexose Correlated Compound (AHCC) in Mice
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Perspective · 10 Sep 2026
Cellular Pathways Involved in Mucosal Immunity and Protection Against Environmental Challenges
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Francisco Karkow”
- BylineArticles whose byline prints “Joel Faintuch”
- BylineArticles whose byline prints “Anil D Kulkarni”

